# Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

> **Open Intelligence Dossier** · First detected: 2026-09-01 17:07 UTC · Category: Business

## Executive Summary
Novartis shares climb following positive late-stage trial results for its experimental oral multiple sclerosis drug, Rhapsido.

## Intelligence Brief
Coverage across specialized and mainstream publications emphasizes that the experimental oral medication met its main goals in late-stage studies by significantly reducing relapse rates and outperforming an approved older therapy in two large trials. Outlets such as Fierce Pharma and Multiple Sclerosis News Today highlight that the Phase 3 trials showed no liver safety signal, with Endpoints News and other sources noting that the data suggest the pill is safer than rivals. Additional reporting from Yahoo Finance and other financial platforms details how TGTX stock pared opening losses after an analyst dismissed competition from Novartis, while Investor's Business Daily notes a six percent surge in Novartis stock and Bloomberg discusses boosted blockbuster prospects for the company's drug pipeline.


Background context within the coverage establishes that these late-stage trials specifically targeted relapsing multiple sclerosis, positioning the BTK inhibitor to compete directly in a major therapeutic market. BioSpace explicitly connects these positive Phase 3 results to an impending commercial and clinical battle with Roche. The company itself characterized the drug in its announcements as a high-efficacy oral BTK inhibitor that not only clears major Phase III hurdles in relapsing MS but also presents a favorable safety profile compared to existing therapeutic options currently available to patients suffering from the condition.


Looking ahead based strictly on the provided headlines, financial analysts and market observers will be tracking the ongoing performance of Novartis stock, potential breakout patterns noted by Investor's Business Daily, and the competitive positioning of TGTX against Novartis. Coverage does not yet specify the precise dates for regulatory submissions or commercial rollouts, leaving the immediate next steps in the hands of regulatory bodies and upcoming corporate disclosures from the pharmaceutical manufacturer concerning Rhapsido and remibrutinib.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Yahoo Finance | Novartis (SWX:NOVN) Reports Two Positive Phase III Results For Oral MS Drug | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxQR2kyNzJjLTVpdjhvclF6VXk4NDgySXljdHVSQWJySXg5XzJiY3lnMEJlbUU2bEJLamV3WjRRR3dvMVA4cEl4LUVDY3hGWmJlYXJWaWF6WHVOcDYydS1OZTFfZGFXSFRjUE1DWEhvdHF4M2VwWWNCS0trYUNrMFVUb2VCMDJ1ZU1DLXJyMkJvTnc5cGV1?oc=5) |
| tipranks.com | Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials | [Source Link](https://news.google.com/rss/articles/CBMiwgFBVV95cUxPVkpzQTJJM29tS0t0ZDNjRUdoX3NsckQ1T1VaZUJBLXRpcVVwRzJiZmxScWczRUd5bEQwVzFJN2xWVXZMRWVPYlhUMzNPZ3NJSXhabElHTGJBbUhqN1NRcEI3bXQ2YU1id2R0VFpreUJpNGpFdDhjMUp6MlEtSkhoVjN4UVl6Rm9VVFRtYUlvRUhRRU9lWFFhQnR0ZUZqdVdHMVFQLVRSYU45RHJpb2hrdG5SNk9lMmpjazNSaHBPQ3pwdw?oc=5) |
| finance.yahoo.com | TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis | [Source Link](https://news.google.com/rss/articles/CBMinAFBVV95cUxPbHBnSWpUMVpKRVZVM1oweGVtaHZWMHR5cnIyX0FtSVlZQjd5LXRKSDRmOTZvcHFoaGRXNjBFLVdLTm92OGVwOXNETklhYklKYzlfX2dSM0w4TnJDRDZYUGRFU1RfcUtKa05QZmZLX0p6aXVsWTV5dHF3QTBabXJwOEVCaFAta0NBa1h6eGdlZ2hoX1FjTWdTSXJxYWg?oc=5) |
| The Pharma Letter | Novartis BTK inhibitor clears Phase III hurdle in relapsing MS | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxPTGNtX25rQWJ2NWJJMm9yT0dCU09WaXBpUGRyUmRxdnlyYzZnNHo4b0dwRmRnT1otSWRIMm9JU1ZDaU9yeTVMcmhGeFJfT2syNERYYk5DUWZzVHZfTm12bTc4MTlxX3lxaWh3ZkQydUxLNDgxWXE3aERtZFpya0N4Ymp2Mlc1YzczMXBybFMyZk9EY1N1LVVqTFEwcG0zRWtjbjVHMmpfclVGQQ?oc=5) |
| Multiple Sclerosis News Today | Experimental oral MS drug outperforms approved therapy in 2 trials | [Source Link](https://news.google.com/rss/articles/CBMixAFBVV95cUxPSWdqT2pfbUVfS2NKUjZCTXlvWWxEWkRlbTh4T0tXaTRwZ0syRlNqcjB4X1lBS2xmaW8weE9BS1dER2l0ZDlDeFJpV2hCX0JIZ3Vmc3h6TUs2V3BoRGlIMmJIREU1U3FKOFNZUlhNWDhicUdyd1I1bGJkUkNyOXpfckxsWUN2QkliZGlVMnE2Nk5tRkJsaDFSTmdzSFl5LTJucXc1N1NfT1Bvb010UVpIQjlxSW1yRUJJTVB1MjRFdjdnYjJX?oc=5) |
| BioSpace | Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle | [Source Link](https://news.google.com/rss/articles/CBMiuwFBVV95cUxOaW9fTzBpZXdabVRlMUUyZEZRZDdjZ3VNOFByUE93SEc1ZmFrajJod29oY3pzM1ZRd19XODRqMlcwbm9CODk2NFVMblFXSUFQWmN4MndVRzBBT0hwSzk3N2YtWm1GNjNIRXNlV3ZFR2EtU0ZuUXFFTHZzLTBXM3hvbnRFckZ4Rl9weThEbTRVZGFUTEpWQlZEZkxNbkNDLXdjVDVzY0doWW9Va0pKTGNIOTBSZzhGN3l5VTEw?oc=5) |
| Fierce Pharma | Novartis claims MS win as Rhapsido clears phase 3 with ‘no liver safety signal’ | [Source Link](https://news.google.com/rss/articles/CBMiugFBVV95cUxNR0Z0UkUxREJpTjVBRS0waFpuaElKbk50X0x6NHV4dVk4bjZNNDlheEdhSnk1M29RNDJmNDJJd29rT1FBT21LT2hrWFlzbkxOSmZFaXlEMjc5bVdBd3NxSHUwLUczUFhOdmZWQUMyX045YmpDY0JIWFdiaU1VRlRvRXphQm9wcFRpYmRVOFJRaDl0QkoteWxzdzN0bXoxOERhcjYtSlVSbFNveFVLaXJDRHBoYzExRUJVb3c?oc=5) |
| FirstWord Pharma | Novartis' Rhapsido delivers dual Phase III wins in relapsing MS | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE56OFZxc09jYzVMd1BFTmhzbmFjUWZuQ2VKVWRCc3h0NGR0Zm5fSzNxOUFKNzhNZXhzWG1Da29QZlRNSXlneFAyNWlUZWh5YTR0UmFV?oc=5) |
| Novartis | Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials | [Source Link](https://news.google.com/rss/articles/CBMimwJBVV95cUxNMEpTYUVaYXUtU1hTeU9xdURGOS1HVUdXbmVBdVBsUlp1VVoyZVVDWGkzYzc1MFBfOGZDdWhsWHpkdXB1Z1cteFdscDRVWnZGMnR0c1p3VVJobG51ME9lMjc4NmU1d0FidzhWZzZDcWt4R0VuOElXUF96UkJoV0hMNHUzSjFpbkVsb3h4b29WdWhKcFNTbmx5b01wRk0tUThaeGg2YlFxZ3dhYTI0cmh6akJfaXRLR3F3VUJCTlNLb1FfaVdJU2s1eVVGYzZvTnZHaEZ0cm5DX3d2RVpsa2FLaGtweE1XZTRpZXJhcW9wM1NfenBCczBKdTJOMUpLQWtMLXh4b1BUV0tTbUpSWkRVMWV2SGFlbUpkRVdz?oc=5) |
| Investopedia | Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug. The Stock Is Jumping | [Source Link](https://news.google.com/rss/articles/CBMi4AFBVV95cUxOZXh6Y0NIelBZRndWU3g2d200VWxwNjcwRUJrSXhwLWtKUnoySXVCTG1RdGYxaUF6N1lwRmRsaHVnZXlCTUZZWjFvWks2UnNjSEhKWXFLV1hMTXpVTzV5UlNaYXlQTXI3MmljTWp3SG5JRjEwYm51UzJqamNrZHpYc1Z6SHp3TkN5NUVsVnRwM3NieGV0TnIwQlJ4TlBZa1pLUHhKeUQwaEVGOWd1T3J1RnNBSk9hWjdSQjZzN0ZCUndIazk4aDdSYnlBR05PMGVhSjJZQnRPU2hiVU1NS3pCUQ?oc=5) |
| pharmaphorum | Novartis sets sights on new oral MS drug after phase 3 wins | [Source Link](https://news.google.com/rss/articles/CBMijwFBVV95cUxOWWk2T0x1eGlLWmZWZUoxUG0zeGRRRG5NVmZySjQ0T2V3WjlQa2xSRU0tODk0OFdpUGdjbE95LS1vb2JVWVRhYnRncmRGMjFZUlFFYTRhUnk4THFKTnQ4enJDeUZPWWxUVkVqTExhZXNPZkY1aHBva21ycUhOcXplSUc3eWpScVZYTHZ3VFhhYw?oc=5) |
| Yahoo Finance | Novartis' oral multiple sclerosis drug meets main goal in late stage studies | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxON2hRUkNGRTA1WDM2TFFLVDBRWE9jaTF4VndJLUx5bkdLcElibU1YSkphS08wb3EySnlHVzVrcTNLYlNGbjhBYnYxQVREbVFaLWo3M3AwV3dwVnctV293YUc4NmtxRWFkeFRXQjBNTHNWM0RTWENPSDI5S2xWTmRLSTU1anltaUZzNExBb01OLW41M3czX1NBcDQxdmkxN0k?oc=5) |
| Endpoints News | Novartis’ Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxNbWY2QnFFcjBmOWJrVHcxQmJjVGRuekFyRDF6M28wdFk4Qk5NQkdxLUxIa2U5eVZKb08tUEVfZkptVTEyQ0dEOS1NWE9sZ0xra0NsUFZhTFV2VkpMZE1USWI5UC1SVXV2R2RPcGEyc2F0cnAySFE1NXczbWR1bDZKR1cxczBSOFcyVGk4UW0wU3ByT1kyamgzV2puWjE1ZXpy?oc=5) |
| BioPharma Dive | Novartis says MS pill succeeds in two large studies | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxQbTJsVUlGNk5pSTk1MFNTZDJ5V1l1V2J5cEJlcU5aMHRqSEZnLUhPeVlxLXVSU2xLaHFJYjV0R090TXhKOWp3MVR3ZU9WZGpQSktlUDd1Mm0xOElLRTRjQWk2ZzA4emdlcE1SdkFmTUx2M1RoQVBxZU9pUVFTSDdnR2VpdnNKd21rQWtIRko2S1BaTG1uZjNXTDZMOTF4ZS1neHRNZ1dhT2l6ZFU?oc=5) |
| Investor's Business Daily | Why Novartis Just Surged 6%, Eyeing A Breakout | [Source Link](https://news.google.com/rss/articles/CBMijwFBVV95cUxNbC1HZnNOR2EzQmJaVF90THJtbDJkV1FQZm9sQkQ3a2hNeTg4QThqdVRQRzJwT0RXS0QwUVVWazU0Q2JUTVVDLXgtM0NJY3JPTkxydWYxNVUzcXl1N0cwNnlreGxrV1RwTW1Fb1pZdnlaNFlzckZBMXVTenVpMHpVUzBuS0FqUmZDQTZQejZ2bw?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-01/novartis-shares-climb-after-pill-hits-goals-in-multiple-sclerosis-trials*